Related Experiment Video
Updated: Aug 4, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
[Agranulocytosis caused by captopril]
Insights
Captopril can cause agranulocytosis, a severe drop in white blood cells, even in patients without risk factors. Careful monitoring and dosage adjustments are crucial when prescribing this hypertension medication.
Area of Science:
- Pharmacology
- Hematology
- Cardiology
Background:
- Captopril is an effective treatment for hypertension and heart failure.
- While generally safe, captopril can cause severe side effects like agranulocytosis.
- Agranulocytosis risk increases with renal insufficiency, collagen diseases, or leucopenic medications.
Observation:
- This case details agranulocytosis secondary to captopril in a patient with heart failure.
- The patient had no pre-existing risk factors for this complication.
- The adverse event did not appear to be dose-related.
Findings:
- Captopril-induced agranulocytosis can occur in patients without typical risk factors.
- The exact mechanism of captopril-induced agranulocytosis remains unclear.
- This case highlights the potential for severe hematologic reactions.
Implications:
- Prescribing captopril requires caution, especially in patients with renal insufficiency or collagen diseases.
- Avoid co-administration with leucopenic medications.
- Individualized hematologic monitoring is essential for patients on captopril.
Abstract:
Captopril, an inhibitor of the conversion enzyme, is a medication with a known efficacy in the treatment of arterial hypertension and congestive cardiac insufficiency. Its side-effects are few. Among them, agranulocytosis is a severe complication, all the more severe and frequent as it occurs in patients with chronic renal insufficiency, collagen disease, or patient treated with medication having a leucopenic potential. Our case reports an agranulocytosis secondary to captopril in a patient with cardiac insufficiency presenting none of these aggravating factors. The mechanism of agranulocytosis secondary to captopril remains currently debatable, but does not seem, in the present case, to be dose related. Thus, a captopril prescription must comply with certain rules; decrease of the dosage in case of renal insufficiency, usual precautions in patients with collagene diseases. The association to a medication with leucopenic potential is to be avoided. Hematologic monitoring will be adapted to each particular case.
Related Concept Videos
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous capillaries...
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention

